Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
| ▸ | PRSS1 | P07477 | 9/20 | 0.47 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | PLG | P00747 | 1/20 | 0.44 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.44 |
| ▸ | C1S | P09871 | 1/20 | 0.44 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29818781 | 1.00 | TAAR1 (0.50) | TAAR1PRSS1PDK2SMN1; SMN2LTA4H | |
| SCHEMBL23116529 | 0.88 | CYSLTR2 (0.54) | TAAR1LTA4HPLA2G2A | |
| SCHEMBL4568923 | 0.85 | KMT2A (0.59) | SMN1; SMN2KMT2A | |
| SCHEMBL611960 | 0.85 | CNR1 (0.50) | TAAR1 | |
| SCHEMBL3179388 | 0.84 | FFAR1 (0.48) | TAAR1LTA4H | |
| SCHEMBL9107098 | 0.83 | TAAR1 (0.70) | TAAR1PRSS1LTA4HPLA2G2A | |
| SCHEMBL29818936 | 0.83 | SMN1; SMN2 (0.52) | PDK2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL2206370 | 0.83 | SMN1; SMN2 (0.52) | PDK2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL2208586 | 0.83 | PPARG (0.47) | TAAR1 | |
| SCHEMBL2205020 | 0.83 | PDK2 (0.49) | PDK2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12029708-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-12029708-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-12029708-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2023-07-13 | — | — | US | disclosed |
| US-11446261-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-20210077427-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2021-03-18 | — | — | US | disclosed |
| US-20210077427-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2021-03-18 | — | — | US | disclosed |
| US-10639286-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2020-05-05 | — | — | US | disclosed |
| US-20120122938-A1 | Alkoxy Compounds for Disease Treatment | ACUCELA INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-7982071-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-7982071-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-7982071-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-20090326074-A1 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090326074-A1 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090326074-A1 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2009-12-31 | — | — | US | disclosed |
| EP-2091955-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | Acucela, Inc. (US) | 2009-08-26 | — | — | EP | disclosed |
| WO-2009045479-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. (US) | 2009-04-09 | — | — | WO | disclosed |
| WO-2009045479-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. (US) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12029708-B2 | Alkoxy compounds for disease treatment | ALDH1A2, CLN6, AGER | TAAR1 1482/4885PRSS1 2965/4885PDK2 496/4885 |
| US-20120122938-A1 | Alkoxy Compounds for Disease Treatment | ALDH1A2, CLN6, AGER | TAAR1 1482/4885PRSS1 2965/4885PDK2 496/4885 |
| US-20210077427-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | TAAR1 1482/4885PRSS1 2965/4885PDK2 496/4885 |
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | TAAR1 1463/4885PRSS1 2926/4885PDK2 502/4885 |
| US-11446261-B2 | Alkoxy compounds for disease treatment | ALDH1A2, CLN6, AGER | TAAR1 1482/4885PRSS1 2965/4885PDK2 496/4885 |
| US-20090326074-A1 | Alkoxy compounds for disease treatment | ALDH1A2, CLN6, AGER | TAAR1 1482/4885PRSS1 2965/4885PDK2 496/4885 |
| US-10639286-B2 | Alkoxy compounds for disease treatment | ALDH1A2, CLN6, AGER | TAAR1 1482/4885PRSS1 2965/4885PDK2 496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.